Physician profile
Patrick L Tassin
NPI 1639412059
$2,077.02
in general payments reported to CMS, 2019-2025
28 companies · $494 in 2025
The $494 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $28.50 · 2021: $302 · 2022: $275 · 2023: $576 · 2024: $139 · 2025: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,208.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $537.79 | 2019-2023 | Liletta, Lo Loestrin Fe, Ubrelvy |
| Amgen INC. | $171.40 | 2019-2025 | Evenity |
| Astellas Pharma US INC | $165.92 | 2023-2025 | Veozah |
| Pfizer INC. | $142.88 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.13 | 2019-2025 | |
| Hologic Sales and Service, LLC | $103.47 | 2021-2025 | Myosure Tissue Removal Device, Aptima, Novasure |
| Mayne Pharma Commercial LLC | $100.40 | 2023-2025 | |
| Myriad Women'S Health, INC. | $98.99 | 2023 | Myrisk |
| Axsome Therapeutics, INC. | $87.89 | 2025 | Auvelity |
| Coopersurgical, INC. | $85.37 | 2021-2025 | Ally II Ups |
| Ethicon US, LLC | $68.98 | 2023-2025 | Stratafix, Vistaseal |
| Avion Pharmaceuticals | $40.89 | 2021 | |
| Novo Nordisk INC | $35.05 | 2023-2025 | Wegovy |
| Amag Pharmaceuticals, INC. | $35.03 | 2019 | |
| Dexcom, INC. | $32.71 | 2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $29.29 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $28.86 | 2023-2024 | Exparel |
| Exeltis, USA INC. | $25.22 | 2021-2022 | |
| Therapeuticsmd, INC. | $22.41 | 2022 | |
| Evofem Biosciences, INC. | $21.86 | 2022 | |
| Scynexis, INC. | $21.63 | 2022 | |
| Sage Therapeutics, LLC | $19.14 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $16.84 | 2021 | |
| Millicent US INC | $16.23 | 2025 | Femlyv |
| Medtronic Vascular, INC. | $15.82 | 2019 | |
| Duchesnay USA Incorporated | $15.25 | 2019 | |
| Boston Scientific Corporation | $13.74 | 2019 | |
| Mallinckrodt Enterprises LLC | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tassin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.